Cyclerion Therapeutics, Inc. (KRSA) vs Septerna, Inc. (SEPN)

Cyclerion Therapeutics, Inc. and Septerna, Inc. are both Biotechnology companies. Cyclerion Therapeutics, Inc. and Septerna, Inc. are of similar size ($1.8B and $1.7B). Septerna, Inc. grew revenue faster over the last twelve months: 13,520.1% against 30.8%. Cyclerion Therapeutics, Inc. has the higher net margin (0.00% vs −24.5%) and the higher return on invested capital (−115.4% vs −189.0%). Across the 15 metrics below, Septerna, Inc. leads on 8 and Cyclerion Therapeutics, Inc. on 7.

Valuation

Metric KRSA SEPN Biotechnology median
P/E n/m n/m 7.88
P/S 9.08 17.20 11.47
P/B 3.70 4.40 2.52
Price to free cash flow n/m 14.47 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 8.41 13.44 10.73
Earnings yield (37.47%) (1.43%) (28.84%)
Free cash flow yield (24.02%) 6.91% (23.03%)

Profitability

Metric KRSA SEPN Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% (44.04%) 0.00%
Net margin 0.00% (24.51%) 0.00%
Free cash flow margin 0.00% 118.93% 0.00%
Return on equity (98.22%) (6.34%) (57.72%)
Return on assets (82.29%) (4.94%) (49.22%)
Return on invested capital (115.40%) (189.01%) 0.00%

Growth

Metric KRSA SEPN Biotechnology median
Revenue growth (TTM) 30.77% 13,520.11% 5.64%
EPS growth (last fiscal year) 8.26% 84.85% —
Revenue growth, 5-year CAGR (14.38%) — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric KRSA SEPN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.82 4.99 4.73
Net debt to EBITDA 0.65 5.86 0.96

Dividend

Metric KRSA SEPN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 — 0.00

Size

Metric KRSA SEPN Biotechnology median
Market cap 1.69b 1.78b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack